Clinical Trials Logo

Glaucoma clinical trials

View clinical trials related to Glaucoma.

Filter by:

NCT ID: NCT06223048 Recruiting - Clinical trials for Primary Open Angle Glaucoma

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

Start date: December 7, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).

NCT ID: NCT06214676 Not yet recruiting - Open Angle Glaucoma Clinical Trials

OCTA in Patients With Primary Open-angle Glaucoma

Start date: April 2024
Phase:
Study type: Observational

Is to investigate retinal microvascular changes in primary open angle glaucoma patients using Optical Coherence Tomography Angiography.

NCT ID: NCT06213896 Completed - Glaucoma Clinical Trials

Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images

Start date: March 1, 2023
Phase:
Study type: Observational

Eye health is of great importance for quality of life. Some eye diseases can progress and cause permanent damage up to vision loss if they are not treated early. Therefore, it is of great importance to have regular eye examinations and to detect possible eye diseases before they progress. Healthy people should also undergo eye screening once a year, and those with any complaints regarding eye health should be examined. With the advancing technology, Artificial Intelligence (AI) has begun to play a significant role in the healthcare sector. Retinal diseases, serious health problems resulting from damage to the back part of the eye's retina, include conditions such as retinopathy, macular degeneration, and glaucoma. Artificial intelligence, with its visual recognition and analysis capabilities, holds great potential in the early diagnosis of retinal diseases. AI-based diagnosis of retinal diseases typically involves the use of specialized algorithms that analyze retinal images. These algorithms identify abnormal features in the eye, providing doctors with a quick and accurate diagnosis. EyeCheckup v2.0 will diagnose glaucoma suspicion, severe glaucoma suspicion, age-related macular degeneration diagnosis, RVO diagnosis, diabetic retinopathy diagnosis and stage, presence/absence of DME suspicion and other retinal diseases from fundus images. This study is designed to assess the safety and efficacy of EyeCheckup v2.0. The study is a single center study to determine the sensitivity and specificity of EyeCheckup to retinal and optic disc diseases. EyeCheckup v2.0 is an automated software device that is designed to analyze ocular fundus digital color photographs taken in frontline primary care settings in order to quickly screen.

NCT ID: NCT06213805 Recruiting - Glaucoma Clinical Trials

Efficacy and Safety of Minimally Invasive Micro-Sclerostomy (MIMS) in Glaucoma Surgery

MIMS
Start date: January 15, 2024
Phase: N/A
Study type: Interventional

The main objective is to evaluate the effectiveness of MIMS in patients with an indication for glaucoma surgery, compared to traditional surgery. The secondary objective is to assess safety. The investigating ophthalmologist will follow the patients and collect clinical data in order to identify the benefits and complications of MIMS. Patients are expected to experience fewer complications compared to traditional glaucoma surgery.

NCT ID: NCT06201455 Recruiting - Clinical trials for Glaucoma, Open-Angle

Evaluation of Phacogoniotomy in Medically-controlled POAG

ECO
Start date: September 28, 2023
Phase: N/A
Study type: Interventional

The goal of this multicenter non-inferiority randomized controlled trial is to compare the efficacy of phacoemulsification with intraocular lens implantation (PEI) combined with goniotomy (GT) and PEI combined with medical therapy (MED) in the treatment of medically-controlled primary open-angle glaucoma (POAG) with cataract. The main questions it aims to answer are: - Whether the PEI+GT was non-inferior to PEI+MED with regard to the intraocular pressure lowering effect in medically-controlled POAG. - Whether the PEI+GT has value of health economics. Participants will be randomized to receive either PEI+GT or PEI+MED, and followed up with a 1-year period as a primary outcome.

NCT ID: NCT06200727 Active, not recruiting - Glaucoma Clinical Trials

Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to observe the role of PRF in treating ophthalmic diseases.The efficacy and safety of PRF were validated for four ophthalmic conditions: macular hole, pterygium, corneal ulcer, and patients undergoing trabeculectomy for glaucoma. The main question aims to answer is PRF's effectiveness in ocular surface and fundus diseases. Participants will be divided into 2 groups, the experimental group will be treated with PRF and the control group will be treated with conventional surgery, with a 12-month postoperative follow-up to determine the role of PRF on wound healing in ophthalmic diseases.

NCT ID: NCT06190119 Recruiting - Glaucoma Clinical Trials

Comparison of Aqueous Humor Adipokines in Glaucoma Patients and Healthy Controls

Start date: October 8, 2023
Phase:
Study type: Observational

The purpose of this study is to observe whether there are differences in adipokines in the aqueous humor between patients with primary open-angle glaucoma (POAG) and healthy controls

NCT ID: NCT06190028 Recruiting - Dry Eye Syndrome Clinical Trials

Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy

Start date: June 14, 2023
Phase: N/A
Study type: Interventional

The main aim of this investigation is to evaluate the effect of the preservative-free ophthalmic solution IRIDIUM® A gel on the ocular surface of patients with glaucoma or OHT and concomitant DES under multiple long-term topical hypotensive therapy for at least 6 months. The underlying assumption is that ophthalmic solutions as adjuvants for the management of IOP- or glaucoma-associated dry eye may induce a protection of the eye surface with consequent improvement of the symptoms and of the overall quality of life.

NCT ID: NCT06189326 Active, not recruiting - Congenital Glaucoma Clinical Trials

Non-penetrating Deep Sclerectomy Versus Trabeculotomy- Trabeculectomy Operation in Treatment of Primary Congenital Glaucoma

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

The high success rate of the non-penetrating deep sclerectomy (NPDS) procedure in adult glaucomatous patients motivated some glaucoma specialists to try it as an alternative procedure in childhood PCG. In deep sclerectomy, the surgeon fashions a partial-thickness scleral flap and excises the outer parts of both Schlemm's canal and trabecular meshwork without opening the eye, leaving a thin trabeculo-descemetic membrane. This membrane will guard against early postoperative hypotony due to the non-penetrating nature of the procedure. The aim of this study is to assess the safety and efficacy outcomes of non-penetrating deep sclerectomy versus combined trabeculotomy-trabeculectomy in the treatment of congenital primary glaucoma

NCT ID: NCT06186388 Recruiting - Glaucoma Clinical Trials

Glaucoma Screening

Start date: December 5, 2023
Phase: N/A
Study type: Interventional

- The primary objective of this study is to evaluate the diagnostic accuracy of the TEMPO (iMOvifa) visual field perimeter screening test by measuring the sensitivity in a population of eyes with glaucoma and the specificity in a population of normal eyes and to measure repeatability of the screening test. - The secondary objective of this study is to gather and analyze ancillary data to confirm the diagnosis or absence of glaucoma.